StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) stock

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.56−0.05 (-7.95%)

Close on Nov 20, 2026Market cap $21.34MP/E –Yield –

Metagenomi Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Metagenomi Therapeutics

Metagenomi Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Metagenomi Therapeutics figures

See a number that looks wrong?